Human Immunodeficiency Virus



Real-world Insights of People With Human Immunodeficiency Virus (HIV) Infection


Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Other: Functional Assessment of HIV Infection;   Other: Patient Satisfaction Questionnaire;   Other: Symptom Distress Module;   Other: Patient Health Questionnaire;   Other: Internalized Stigma of AIDS Tool;   Other: Medication adherence visual analogue scale
Sponsors:   ViiV Healthcare;   Evidera;   mProve
Not yet recruiting


Feasibility of Telerehabilitation in HIV-patients


Condition:   Human Immunodeficiency Virus
Intervention:   Behavioral: Endurance ad Resistance Training Exercise
Sponsor:   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Completed


A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment


Condition:   Human Immunodeficiency Virus
Interventions:   Biological: Ad26.Mos4.HIV;   Biological: MVA-Mosaic;   Biological: Clade C gp140 + Mosaic gp140;   Drug: Placebo
Sponsors:   Janssen Vaccines & Prevention B.V.;   Beth Israel Deaconess Medical Center;   Ragon Institute of MGH, MIT and Harvard;   US Military HIV Research Program
Not yet recruiting


Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults


Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: Cabotegravir Tablets;   Drug: Rilpivirine Tablets;   Drug: Cabotegravir Injectable Suspension;   Drug: Rilpivirine Injectable Suspension
Sponsors:   ViiV Healthcare;   Janssen Research and Development
Recruiting


Innovations in HIV Testing (TI)


Condition:   Human Immunodeficiency Virus
Interventions:   Diagnostic Test: Oraquick HIV Self Test - Choice;   Diagnostic Test: Atomo HIV Self Test - Choice;   Diagnostic Test: Oraquick HIV Self Test and Atomo HIV Self Test - Both
Sponsors:   University of North Carolina, Chapel Hill;   University of Witwatersrand, South Africa;   University of California, San Francisco;   National Institutes of Health (NIH);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Completed


A Combination HIV Prevention Strategy for Young Women at Risk for HIV


Condition:   Human Immunodeficiency Virus
Intervention:  
Sponsor:   Columbia University
Recruiting


Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms


Conditions:   HIV (Human Immunodeficiency Virus);   AIDS (Acquired Immunodeficiency Syndrome)
Interventions:   Device: VIP app without HIV-related symptom strategies.;   Device: VIP app that delivers HIV-related symptom strategies.
Sponsors:   Columbia University;   National Institute of Nursing Research (NINR)
Recruiting


Innovations in HIV Testing


Condition:   Human Immunodeficiency Virus
Interventions:   Diagnostic Test: Oraquick HIV Self Test;   Diagnostic Test: Clinic Based HIV Counseling and Testing (HCT)
Sponsors:   University of North Carolina, Chapel Hill;   University of Witwatersrand, South Africa;   University of California, San Francisco;   National Institutes of Health (NIH);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting


Partners-based HIV Treatment for Couples Attending Antenatal Care


Condition:   Human Immunodeficiency Virus
Intervention:   Behavioral: Couples-based services
Sponsors:   Vanderbilt University Medical Center;   National Institute of Mental Health (NIMH)
Not yet recruiting


Secondary Distribution of HIV Self-tests: an Innovative Strategy for Promoting Partner Testing and Reducing HIV Risk


Condition:   Human Immunodeficiency Virus
Intervention:   Behavioral: Provision of multiple self-tests
Sponsors:   University of North Carolina, Chapel Hill;   National Institute of Mental Health (NIMH);   Impact Research & Development Organization;   RTI International
Recruiting


Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults


Condition:   Human Immunodeficiency Virus
Interventions:   Biological: Ad26.Mos.HIV;   Biological: MVA-Mosaic;   Drug: Placebo
Sponsor:   Janssen Vaccines & Prevention B.V.
Active, not recruiting


mVIP (Use of mHealth Technology for Supporting Symptom Management in Underserved Persons Living With HIV)


Condition:   HIV (Human Immunodeficiency Virus)
Interventions:   Device: Health Management App with symptom strategies;   Device: My Fitness Pal App
Sponsor:   Columbia University
Completed


3BNC117 and 10-1074 in HIV Uninfected Adults


Condition:   Human Immunodeficiency Virus
Interventions:   Drug: 3BNC117;   Drug: 10-1074;   Drug: Placebo
Sponsor:   Rockefeller University
Active, not recruiting


A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in the Rilpivirine Pediatric Studies


Condition:   Human Immunodeficiency Virus Type 1
Intervention:   Drug: Rilpivirine
Sponsor:   Janssen Sciences Ireland UC
Recruiting


Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV


Condition:   Human Immunodeficiency Virus
Interventions:   Drug: emtricitabine/tenofovir;   Behavioral: CBT-based counseling
Sponsors:   Ronald Stall;   Fenway Community Health;   National Institute of Mental Health (NIMH)
Active, not recruiting


Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen


Condition:   Infection, Human Immunodeficiency Virus
Intervention:   Drug: Subjects do not receive study medication in this study 202094
Sponsors:   ViiV Healthcare;   Janssen Pharmaceuticals;   GlaxoSmithKline
Active, not recruiting


Regular HIV Testing Among At-Risk Latino Men


Condition:   Human Immunodeficiency Virus (HIV)
Interventions:   Behavioral: Social Network;   Behavioral: Comparison
Sponsors:   Medical College of Wisconsin;   National Institute of Mental Health (NIMH)
Enrolling by invitation


Cognitive-Based Compassion Training (CBCT) for People Living With HIV (PLHIV)


Condition:   Human Immunodeficiency Virus
Interventions:   Behavioral: Cognitive-Based Compassion Training (CBCT);   Behavioral: Health discussion
Sponsor:   Emory University
Completed


Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants


Condition:   Human Immunodeficiency Virus Type 1
Interventions:   Drug: D/C/F/TAF;   Drug: Boosted Protease Inhibitor (bPI);   Drug: FTC/TDF
Sponsor:   Janssen R&D Ireland
Active, not recruiting


Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)


Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: 744 Tablet;   Drug: 744 LA Injection;   Drug: Placebo Tablet;   Drug: Placebo Injection
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Completed


Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus


Condition:   HIV
Interventions:   Drug: antiretroviral therapy;   Behavioral: cell phone reminders;   Behavioral: contingency management for adherence
Sponsors:   UConn Health;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting


CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)


Condition:   Human Immunodeficiency Virus
Interventions:   Device: Intervention Arm (computer-based CARE+ Corrections tool);   Other: Educational video on opiate overdose prevention
Sponsors:   George Washington University;   The Miriam Hospital;   New York University
Completed


Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine


Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: GSK1265744 10 mg;   Drug: GSK1265744 30 mg;   Drug: GSK1265744 60 mg;   Drug: Efavirenz 600 mg;   Drug: Rilpivirine 25 mg;   Drug: Placebo;   Drug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Active, not recruiting


Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)


Condition:   Human Immunodeficiency Virus (HIV)
Interventions:   Drug: Darunavir/Ritonavir (DRV/r);   Drug: Lopinavir in fixed combination with Ritonavir;   Drug: Zidovudine;   Drug: NRTIs;   Drug: Efavirenz
Sponsor:   Janssen-Cilag G.m.b.H
Completed


An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children


Condition:   Human Immunodeficiency Virus
Intervention:   Drug: Maraviroc
Sponsors:   ViiV Healthcare;   Pfizer
Active, not recruiting

Refine Your Search Advanced Search